Hypochlorous acid is nature’s own germ-killer — the same molecule your immune system deploys — but for a century it stayed a laboratory curiosity, because no one could make enough of it affordably, and it lost its power the moment it dried. MedeSol’s two platforms overcome both limits.
The differentiator is how MedeSol makes it. Advanced electrolytic systems with precise process control deliver pure, stable HOCl at high daily volume with simple operation — a facility generating its own supply on demand, from salt and water, at near-zero marginal cost. And because it’s produced right where it’s used, on-site generation spares the waste and logistics of countless single-use bottles — shipped, stored, and thrown away.
Each system also produces a second stream — a mild alkaline (sodium hydroxide, NaOH) cleaner that cuts grease and soil, yet is residue-free and gentle on skin and the environment. In MedeSol’s internal testing it performs on par with leading commercial cleaners, so a single installation can replace a facility’s entire inventory of degreasers and detergents alongside its disinfectants — and the cleaning power of electrolyzed alkaline water is well documented in the peer-reviewed literature. Where on-site generation isn’t the right fit, HOCl is bottled under the MedeSol label at Alden Medical’s FDA-registered facility.
For the first time, active compounds can be coated onto surfaces that keep generating HOCl long after they dry. One patent-pending chemistry runs across formats — wound dressings, odor-control hygiene materials, active food packaging, and the consumer sprays behind OdorSol®.
Because it’s licensed into partners’ existing products, Genesis™ earns royalties with no cost of goods. Its flagship licensing opportunity is active food packaging — the chemistry embedded into a manufacturer’s meat pads or produce sachets to slow spoilage and reduce microbial load from inside the package. MedeSol’s internal testing supports the approach, which is now advancing toward its first packaging-manufacturer license.
MedeSol’s platforms are protected by multiple U.S. and international patents pending, and developed alongside leading academic research partners, including the University of Washington and Cardiff Metropolitan University. The peer-reviewed evidence base for HOCl is public — and growing.
See the science →